drugset / Trial / NCT05366816
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research is to test if mutations (changes in DNA) in exons (segment of DNA or RNA containing information that has the instructions for making proteins) in the KIT gene can be used to predict the body's response to standard of care treatment.
Timeline
- Start
- 2023-10-17
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 120 mg | Oral |
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |